It is well documented that enhancing immune function to cancer can have a therapeutic effect on the disease. A major limitation of immunotherapy is the added dimension that the tumor microenvironment can be immune-suppressive to the host that harbors cancer. Recently, there have been a number of approaches to try and """"""""supercharge"""""""" the immune system to tumor Ag(s), so that when the immune system recognizes a tumor it can overcome immune-suppression and destroy the tumor. One approach that has successfully enhanced immune function in tumor-bearing hosts has been the addition of activating antibodies or ligands to TNF-receptor family members. This grant application will focus on the immune boosting activity of the TNF-R family member OX40 (CD134), which is expressed on activated T cells. When OX40 is engaged via an exogenous source of Ab or the OX40 ligand, potent anti-tumor properties are elicited. We will try and understand how OX40 engagement enhances immune function and use this knowledge to increase anti-tumor immunity. Gene array analysis in basic immune models has provided clues to how engagement of OX40 boosts immunity. This application will use the knowledge derived from the basic immunology models to enhance OX40-mediated tumor therapy through combination therapy with the cytokines that show a common gamma-chain (IL-2, IL-7, and IL-15). These cytokine receptors were found to be increased on Ag-stimulated T cells following OX40 engagement in our preliminary DNA microarray analyses. We will also try and understand the changes in T cell gene expression that occur in a tumor microenvironment upon OX40 engagement in vivo. Finally, because the OX40 technology will be taken to clinical trials within the coming year, we will work with an established method for enhancing immune function in clinical trials (i.e. GM-CSF transfected tumors) to assess its augmentation with anti-OX40. This will provide important preclinical information for the design of future clinical trials.
The specific aims of the application are; 1) To characterize the molecular events that occur following OX40 engagement within T cells isolated from a tumor microenvironment, 2) To define the roles of common gamma-chain cytokines in OX40-enhanced anti-tumor immune responses, and 3) Explore the combination of anti-OX40 and a GM-CSF secreting tumor vaccine in a preclinical setting. The ultimate goal of the application will be to enhance OX40-mediated tumor therapy by gaining a better understanding of how this receptor can increase the proinflammatory properties of T cell function. ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA102577-03
Application #
6911614
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Program Officer
Welch, Anthony R
Project Start
2003-07-01
Project End
2008-04-30
Budget Start
2005-07-01
Budget End
2006-04-30
Support Year
3
Fiscal Year
2005
Total Cost
$316,618
Indirect Cost
Name
Providence Portland Medical Center
Department
Type
DUNS #
099142093
City
Portland
State
OR
Country
United States
Zip Code
97213
Duhen, Thomas; Duhen, Rebekka; Montler, Ryan et al. (2018) Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors. Nat Commun 9:2724
Moran, Amy E; Polesso, Fanny; Weinberg, Andrew D (2016) Immunotherapy Expands and Maintains the Function of High-Affinity Tumor-Infiltrating CD8 T Cells In Situ. J Immunol 197:2509-21
Moran, Amy E; Kovacsovics-Bankowski, Magdalena; Weinberg, Andrew D (2013) The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy. Curr Opin Immunol 25:230-7
Gough, Michael J; Killeen, N; Weinberg, Andrew D (2012) Targeting macrophages in the tumour environment to enhance the efficacy of ýýOX40 therapy. Immunology 136:437-47
Redmond, William L; Triplett, Todd; Floyd, Kevin et al. (2012) Dual anti-OX40/IL-2 therapy augments tumor immunotherapy via IL-2R-mediated regulation of OX40 expression. PLoS One 7:e34467
Garrison, Kendra; Hahn, Tobias; Lee, Wen-Cherng et al. (2012) The small molecule TGF-? signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis. Cancer Immunol Immunother 61:511-21
Wu, Xiumei; Rosenbaum, James T; Adamus, Grazyna et al. (2011) Activation of OX40 prolongs and exacerbates autoimmune experimental uveitis. Invest Ophthalmol Vis Sci 52:8520-6
Weinberg, Andrew D; Morris, Nicholas P; Kovacsovics-Bankowski, Magdalena et al. (2011) Science gone translational: the OX40 agonist story. Immunol Rev 244:218-31
Vasilevsky, Nicole A; Ruby, Carl E; Hurlin, Peter J et al. (2011) OX40 engagement stabilizes Mxd4 and Mnt protein levels in antigen-stimulated T cells leading to an increase in cell survival. Eur J Immunol 41:1024-34
Karulf, Matthew; Kelly, Ann; Weinberg, Andrew D et al. (2010) OX40 ligand regulates inflammation and mortality in the innate immune response to sepsis. J Immunol 185:4856-62

Showing the most recent 10 out of 22 publications